Bio Green Med Solution, Inc.

Regulatory Filings • Jun 7, 2012

8-K 1 a12-14320_18k.htm 8-K

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*Washington, D.C. 20549*

*FORM 8-K*

*CURRENT REPORT*

*Pursuant to Section 13 or 15(d)*

*of the Securities Exchange Act of 1934*

Date of Report (Date of earliest event reported): June 7, 2012

*CYCLACEL PHARMACEUTICALS, INC.*

(Exact name of registrant as specified in its charter)

Delaware	0-50626	91-1707622
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

200 Connell Drive, Suite 1500 Berkeley Heights, NJ 07922 (Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (908) 517-7330

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\107256\12-14320-1\task5388675\14320-1-ba.htm',USER='107256',CD='Jun 7 19:16 2012'

*Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.*

On June 6, 2012, Daniel K. Spiegelman resigned from the Board of Directors of Cyclacel Pharmaceuticals, Inc. (the “Company”) due to his appointment as chief financial officer of a publicly traded company. During his tenure with the Company, Mr. Spiegelman also served as the Chairman of the Audit Committee and a member of the Nominating and Corporate Governance Committee of the Board of Directors of the Company.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\107256\12-14320-1\task5388675\14320-1-ba.htm',USER='107256',CD='Jun 7 19:16 2012'

*SIGNATURES*

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

By:	/s/ Paul McBarron
Name:	Paul McBarron
Title:	Executive Vice President—Finance,
	Chief Financial Officer and
	Chief Operating Officer
Date: June 7, 2012

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\107256\12-14320-1\task5388675\14320-1-ba.htm',USER='107256',CD='Jun 7 19:16 2012'